OIA
ENTA icon

Optimum Investment Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Optimum Investment Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-700
Closed -$30K – 931
2014
Q2 		$30K Hold
700
– – 0.01% 584
2014
Q1 		$28K Hold
700
– – 0.01% 457
2013
Q4 		$19K Buy
+700
New +$17K 0.01% 527

Other funds holding ENTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

Optimum Investment Advisors's ENTA Position: Q3 2014 in Review

Optimum Investment Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q3 2014, closing a stake of 700 shares — an estimated $30K sold.

Optimum Investment Advisors first reported a position in ENTA in Q4 2013 and held it in 3 quarters. The position peaked at $30K in Q2 2014. 111 funds tracked by Wall St. Rank hold ENTA as of Q3 2014.

  • Optimum Investment Advisors reported no remaining Enanta Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Optimum Investment Advisors sold 700 Enanta Pharmaceuticals shares in Q3 2014, an estimated $30K.
  • Optimum Investment Advisors first reported a position in Enanta Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • Optimum Investment Advisors's Enanta Pharmaceuticals position peaked at $30K in Q2 2014.
  • 111 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2014.

Based on Optimum Investment Advisors's 13F filing for Q3 2014, filed 17 Nov 2014.